We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SM17, a new IL‐17RB‐targeting antibody, ameliorates disease progression in a mouse model of atopic dermatitis.
- Authors
Lam, Lik Hang; Li, Weimin; Wu, Wai Chung; Chow, Kai Cheung; Au, Wai Yin Dennis; Xu, Guolin; Wang, Ge; Qian, Xuchen; Ng, Ka Man; Nawabjan, Shaik Abdullah; Gandhi Sethuraman, Muthu Iswarya; Choi, Wai Yan; Chow, Billy Kwok Chong; Leung, Shui On; Hui, Chin Wai
- Abstract
The article discusses a new antibody called SM17 that targets IL-17RB and its potential in treating atopic dermatitis (AD). The study found that SM17 could inhibit the release of Th2 cytokines and suppress the proliferation of ILC2 and Th2 cells. In a mouse model of AD, SM17 demonstrated beneficial effects in reducing skin inflammation, epidermal hyperplasia, and eosinophil infiltration. The study suggests that SM17 may be a promising treatment option for AD with enhanced therapeutic effects and a superior safety profile compared to current treatments.
- Subjects
ATOPIC dermatitis; DISEASE progression; LABORATORY mice; ANIMAL disease models; TH2 cells; AUTOIMMUNE diseases
- Publication
Allergy, 2024, Vol 79, Issue 6, p1625
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.16120